Onco Therapies, a wholly owned subsidiary of Stride Arcolab has received ANDA approval for Ifosfamide Injection 50 mg/ mL packaged in 1 gram / 20 mL and 3 grams / 60 mL Single – dose vials.
Ifosfamide is part of the Oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.
According to IMS data, the US market for generic Ifosfamide is approximately $15 Million.